| abstract |
Described herein are a series of Dual-Action Vaccine strategies that combine different components of HIV-1 virus and EBOV envelop glycoprotein (Ebola-GP) to generate a multiple-cycle replicating Ebola- GP/HIV chimeric virus, a single-cycle replicating Ebola-GP/HIV chimeric virus, and a non-replicating chimeric virus. All of these constructs produce GP/HIV chimeric virus-like particles (VLPs) that can efficiently target human antigen-presenting cells (APCs), including dendritic cells and monocyte-derived macrophages, and CD4 negative cells. |